These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28976989)

  • 1. Vitamin D and methylarginines in chronic kidney disease (CKD).
    Torino C; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
    PLoS One; 2017; 12(10):e0185449. PubMed ID: 28976989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D receptor activation by paricalcitol and insulin resistance in CKD.
    Spoto B; Pizzini P; Cutrupi S; Tripepi G; Curatola G; Mallamaci F; Zoccali C
    Nutr Metab Cardiovasc Dis; 2018 Mar; 28(3):291-297. PubMed ID: 29307660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure.
    MacAllister RJ; Rambausek MH; Vallance P; Williams D; Hoffmann KH; Ritz E
    Nephrol Dial Transplant; 1996 Dec; 11(12):2449-52. PubMed ID: 9017621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paricalcitol and endothelial function in chronic kidney disease trial.
    Zoccali C; Curatola G; Panuccio V; Tripepi R; Pizzini P; Versace M; Bolignano D; Cutrupi S; Politi R; Tripepi G; Ghiadoni L; Thadhani R; Mallamaci F
    Hypertension; 2014 Nov; 64(5):1005-11. PubMed ID: 25259743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.
    Nanayakkara PW; Kiefte-de Jong JC; ter Wee PM; Stehouwer CD; van Ittersum FJ; Olthof MR; Teerlink T; Twisk JW; van Guldener C; Smulders YM
    Am J Kidney Dis; 2009 Jan; 53(1):41-50. PubMed ID: 18786751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGF23 and the PTH response to paricalcitol in chronic kidney disease.
    D'Arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
    Eur J Clin Invest; 2020 Feb; 50(2):e13196. PubMed ID: 31863599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients.
    Fleck C; Janz A; Schweitzer F; Karge E; Schwertfeger M; Stein G
    Kidney Int Suppl; 2001 Feb; 78():S14-8. PubMed ID: 11168976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Vitamin D3 on asymmetric- and symmetric dimethylarginine in arterial hypertension.
    Grübler MR; Gaksch M; Kienreich K; Verheyen ND; Schmid J; Müllner C; Richtig G; Scharnagl H; Trummer C; Schwetz V; Meinitzer A; Pieske B; März W; Tomaschitz A; Pilz S
    J Steroid Biochem Mol Biol; 2018 Jan; 175():157-163. PubMed ID: 28027911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
    Emrich IE; Zawada AM; Martens-Lobenhoffer J; Fliser D; Wagenpfeil S; Heine GH; Bode-Böger SM
    Clin Res Cardiol; 2018 Mar; 107(3):201-213. PubMed ID: 29101459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of arginine derivatives in pediatric patients with chronic kidney disease using high-performance liquid chromatography-tandem mass spectrometry.
    Wang S; Vicente FB; Miller A; Brooks ER; Price HE; Smith FA
    Clin Chem Lab Med; 2007; 45(10):1305-12. PubMed ID: 17663630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study.
    Aucella F; Maas R; Vigilante M; Tripepi G; Schwedhelm E; Margaglione M; Gesualdo L; Boeger R; Zoccali C
    Atherosclerosis; 2009 Dec; 207(2):541-5. PubMed ID: 19501358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymmetric dimethylarginine, vascular calcifications and parathyroid hormone serum levels in hemodialysis patients.
    Coen G; Mantella D; Sardella D; Beraldi MP; Ferrari I; Pierantozzi A; Lippi B; Di Giulio S
    J Nephrol; 2009; 22(5):616-22. PubMed ID: 19809994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol.
    Moe SM; Zekonis M; Harezlak J; Ambrosius WT; Gassensmith CM; Murphy CL; Russell RR; Batiuk TD
    Am J Kidney Dis; 2001 Oct; 38(4):792-802. PubMed ID: 11576883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active vitamin D treatment in CKD patients raises serum sclerostin and this effect is modified by circulating pentosidine levels.
    Torino C; Pizzini P; Cutrupi S; Tripepi G; Mallamaci F; Thadhani R; Zoccali C
    Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):260-266. PubMed ID: 28017524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study.
    Saran R; Novak JE; Desai A; Abdulhayoglu E; Warren JS; Bustami R; Handelman GJ; Barbato D; Weitzel W; D'Alecy LG; Rajagopalan S
    Nephrol Dial Transplant; 2003 Nov; 18(11):2415-20. PubMed ID: 14551376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimethylarginine levels and nutritional status in hemodialysis patients.
    Cupisti A; Saba A; D'Alessandro C; Meola M; Panicucci E; Panichi V; Raffaelli A; Barsotti G
    J Nephrol; 2009; 22(5):623-9. PubMed ID: 19809995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD.
    Al-Aly Z; Qazi RA; González EA; Zeringue A; Martin KJ
    Am J Kidney Dis; 2007 Jul; 50(1):59-68. PubMed ID: 17591525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.
    Thadhani R; Appelbaum E; Pritchett Y; Chang Y; Wenger J; Tamez H; Bhan I; Agarwal R; Zoccali C; Wanner C; Lloyd-Jones D; Cannata J; Thompson BT; Andress D; Zhang W; Packham D; Singh B; Zehnder D; Shah A; Pachika A; Manning WJ; Solomon SD
    JAMA; 2012 Feb; 307(7):674-84. PubMed ID: 22337679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.